ClinicalTrials.gov
ClinicalTrials.gov Menu

Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma (TriMix-Ipi)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01302496
Recruitment Status : Completed
First Posted : February 24, 2011
Last Update Posted : May 24, 2017
Sponsor:
Collaborator:
Vrije Universiteit Brussel
Information provided by (Responsible Party):
Bart Neyns, Universitair Ziekenhuis Brussel

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : October 2013
  Actual Study Completion Date : January 2017